本文原文“Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study”,首次发表在Journal of Clinical Oncology,2020,38(1...
本文原文“Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study”,首次发表在Journal of Clinical Oncology,2022,40(7):752-761;本次二次发表已取得版权所有者...
参考文献 Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. [J]The Lancet Oncology...
参考文献: Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;S1470-2045(20)30445-9. ChosenOne599®泛癌种基因检测产品...
KEYNOTE-158(NCT02628067)是一项单臂、开放标签的II期篮子研究(basket study),评价帕博利珠单抗(Pembrolizumab,一种IgG4抗PD-1单克隆抗体)在初治或经治的11种实体瘤的晚期患者的抗肿瘤活性,纳入的癌种包括肛门鳞状细胞癌、胆囊腺癌(胆囊或胆道(肝内或肝外胆管癌)除了壶腹以外)、肺、阑尾、小肠,结肠,直肠或胰腺的...
您好,KEYNOTE-158与028在本质上属于完全不同的范畴,一个是医学研究项目,一个是电话区号,具体区别如下: KEYNOTE-158: 性质:这是一项单臂、开放标签的II期篮子研究(basket study),主要评价帕博利珠单抗(一种IgG4抗PD-1单克隆抗体)在多种实体瘤晚期患者中的抗肿瘤活性。 纳入癌种:包括肛门鳞状细胞癌、胆囊腺癌、...
Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study. J Clin Oncol 2018;36(15_suppl):5522.Chung HC, Schellens JHM, Delord JP et al. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study. ...
In this study, there was close to 50% response rate. The duration response, as reported in that review paper, wasn’t reached, meaning that they have incredible durable responses because once you activate those T cells, they keep fighting the tumor. The overall response had not been reached...
Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. [J]The Lancet Oncology, 2020, 21(10): 135...
O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. J Clin Oncol. 2022 Jan 6:JCO2101874. doi: 10.1200/JCO.21.01874. Epub ahead of print. PMID: 34990208....